DERM(DERM)
DERM
Q4 2026 EPS Estimate
$0.02
Nov 11, 2026 · Reports after close
Revenue Estimate
$22M
FY2027E EPS$0.68
FY2028E EPS$1.66
Analyst Sentiment
Wall St. Consensus
Buy3 analysts·Low coverage
75
Score
3 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
3100%
Hold
00%
Sell
00%
Strong Sell
00%
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price Target Expectations
Bear
$10.50
+35.8%
Consensus
$11.75
+52.0%
Bull
$13.00
+68.2%
12-Month Target Range3 analysts
$10.50$11.75$13.00
Current $7.73Consensus
Current Price
$7.73
Upside to Consensus
$4.02
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
Earnings & Revenue Estimates
Forward Growth Estimates (YoY)
FY2027
Rev+60.28%
EPS—
FY2028
Rev+51.04%
EPS+144.28%
FY2029
Rev+13.20%
EPS+20.54%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
| Metric | FY2026E | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|---|
| Revenue Avg | $81M | $130M | $197M | $223M | $238M |
| Low | $80M | $119M | $192M | $205M | $220M |
| High | $83M | $141M | $202M | $245M | $262M |
| EBITDA Avg | $-16M | $-26M | $-40M | $-45M | $-48M |
| Low | $-17M | $-29M | $-41M | $-50M | $-53M |
| High | $-16M | $-24M | $-39M | $-42M | $-44M |
| EBIT Avg | $-21M | $-34M | $-51M | $-58M | $-62M |
| Low | $-21M | $-37M | $-52M | $-63M | $-68M |
| High | $-21M | $-31M | $-50M | $-53M | $-57M |
| Net Income Avg | $-857,429 | $17M | $41M | $49M | $52M |
| Low | $-3M | $13M | $40M | $44M | $47M |
| High | $857,429 | $20M | $41M | $55M | $59M |
| EPS Avg | $-0.04 | $0.68 | $1.66 | $2.00 | $2.13 |
| Low | $-0.10 | $0.54 | $1.65 | $1.79 | $1.91 |
| High | $0.04 | $0.81 | $1.66 | $2.25 | $2.40 |
| Analysts (Rev / EPS) | 3 / 3 | 3 / 3 | 2 / 2 | 1 / 1 | 1 / 1 |
Quarterly
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $22M | $25M | $25M | $29M | $33M | $35M |
| Low | $21M | $25M | $24M | $27M | $31M | $33M |
| High | $23M | $25M | $27M | $30M | $35M | $37M |
| EBITDA Avg | $-4M | $-5M | $-5M | $-6M | $-7M | $-7M |
| Low | $-5M | $-5M | $-5M | $-6M | $-7M | $-8M |
| High | $-4M | $-5M | $-5M | $-5M | $-6M | $-7M |
| EBIT Avg | $-6M | $-6M | $-6M | $-7M | $-9M | $-9M |
| Low | $-6M | $-7M | $-7M | $-8M | $-9M | $-10M |
| High | $-5M | $-6M | $-6M | $-7M | $-8M | $-9M |
| Net Income Avg | $412,405 | $1M | $1M | $3M | $5M | $5M |
| Low | $206,202 | $412,405 | $1M | $3M | $4M | $5M |
| High | $443,746 | $2M | $1M | $3M | $5M | $5M |
| EPS Avg | $0.01 | $0.04 | $0.04 | $0.10 | $0.17 | $0.18 |
| Low | $0.01 | $0.01 | $0.04 | $0.09 | $0.16 | $0.17 |
| High | $0.02 | $0.06 | $0.05 | $0.11 | $0.18 | $0.20 |
| Analysts (Rev / EPS) | 3 / 3 | 3 / 3 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 |